The creation of retatrutide, a novel dual stimulant targeting both GLP-1 and GIP receptors, involves a complex complicated chemical process. Early routes focused on amino acid chain portion coupling, utilizing solid-phase creation methodologies to build the long amino acid sequence. Subsequent research has explored various approaches, including enz